How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?

Seminars in Dialysis

Volumn 18, Issue 3, 2005, Pages 226-238

  Shahapuni, Irina ^a   Mansour, Janet ^a   Harbouche, Laïd ^a   Maouad, Bechir ^a   Benyahia, Mohamed ^a   Rahmouni, Khelifa ^a   Oprisiu, Roxana ^a   Bonne, Jean François ^a   Monge, Matthieu ^a   El Esper, Najeh ^a   Presne, Claire ^a   Moriniere, Philippe ^a   Choukroun, Gabriel ^a   Fournier, Albert ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; 25 HYDROXYVITAMIN D; ALFACALCIDOL; ALUMINUM HYDROXIDE; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM PHOSPHATE; CINACALCET; FERRIC HYDROXIDE; LANTHANUM CARBONATE; NICOTINAMIDE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D; VITAMIN D DERIVATIVE;

BLOOD VESSEL CALCIFICATION; BONE DENSITY; BONE REMODELING; CALCIUM ABSORPTION; CALCIUM INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; FRACTURE; GASTROINTESTINAL ABSORPTION; GENE DELETION; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; LONG TERM CARE; OSTEOLYSIS; OSTEOMALACIA; OSTEOPENIA; PARATHYROID HYPERPLASIA; PARATHYROIDECTOMY; REVIEW; VITAMIN D DEFICIENCY;

CALCIUM; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS;

EID: 20544461580     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2005.18318.x     Document Type: Review

References (108)

1. Urena P, Frazao JM: Calcimimetic agents: review and perspectives. Kidney Int Suppl 85:S91-S96, 2003
2. Hofer AM, Brown EM: Extracellular calcium sensing and signalling. Nat Rev Mol Cell Biol 4:530-538, 2003
3. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516-1525, 2004
4. Moe SM, Sprague SM, Cunningham J, Drueke T, Adler S, Rosansky SJ, Albizem MB, Guo MD, Zani V, Goodman WG: Long-term treatment of secondary hyperparathyroidism (HTP) with the calcimimetic cinacalcet HCl. J Am Soc Nephrol 14:463-464A, 2003
5. Curhan G: Fooling the parathyroid gland - will there be health benefits? N Engl J Med 350:1565-1567, 2004
6. National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(suppl 3):S1-S201, 2003
7. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208-2218, 2004
8. Sherrard DJ: Aluminum - much ado about something. N Engl J Med 324:558-559, 1991
9. Stevens L, Djurdejv O, Cardew S, Carmeron E, Levin A: Calcium, phosphate and parathyroid hormone levels in combination as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcome. J Am Soc Nephrol 15:770-779, 2004
10. Solal ME, Sebert JL, Boudailliez B, Marie A, Moriniere P, Gueris J, Bouillon R, Fournier A: Comparison of intact, midregion, and carboxy terminal assays of parathyroid for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 73:516-524, 1991
11. Fournier A, Moriniere P, Coevoet B, De Frémont J, Sebert J: Prevention and medical treatment of hyperparathyroidism secondary to renal failure in the adult. In: Hamburger J (ed). Advances in Nephrology. Chicago: Year-Book Medical, 1982:241-268
12. Sebert JL, Marie A, Gueris J, Herve MA, Leflon P, Garabedian M, Smadja A, Fournier A: Assessment of the aluminum overload and of its possible toxicity in asymptomatic uremic patients: evidence for a depressive effect on bone formation. Bone 6:373-375, 1985
13. Fournier A, Solal ME, Oprisiu R, Mazouz H, Morinire P, Choukroun G, Bouillon R: Optimal range of plasma concentration of true 1-84 parathyroid hormone in patients on maintenance dialysis. J Clin Endocrinol Metab 86:1840-1842, 2001
14. Gonzalez EA, Martin KJ: Coordinate regulation of PTH/PTHrP receptors by PTH and calcitriol in UMR 106-01 osteoblast-like cells. Kidney Int 50:63-70, 1996
15. Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, Josse S, Meyrier A, Lins RL, Fairey IT: Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310(6976):358-363, 1995
16. Urena P, Bernard-Poenaru O, Cohen-Solal M, de Vernejoul MC: Plasma bone-specific alkaline phosphatase changes in hemodialysis patients treated by alfacalcidol. Clin Nephrol 57:261-273, 2002
17. Ghazali A, Fardellone P, Pruna A, Atik A, Garbedian M, Fournier A: Is low plasma 25-(OH) vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int 55:2169-2177, 1999
18. Harris SS, Soteriades E, Coolidge JA, Mudgal S, Dawson-Hughes B: Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population. J Clin Endocrinol Metab 85:4125-4130, 2000
19. Fournier A, Said S, Ghazali A, Sechet A, Ezaitouni F, Marie A, Westeel PF, Moriniere P, Boudailliez B: The clinical significance of adynamic bone disease in uremia. Adv Nephrol Necker Hosp 27:131-166, 1997
20. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
21. Peers E, Chapman A, Brown C, Rhodes N: Effect of a new anion exchange compound on phosphate levels in man. XLI Congress ERA, Lisbon, 2004:102
22. Hergesell O, Ritz E: Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant 14:863-867, 1999
23. Freemont A, Jones C: The effects of the phosphate binders lanthanum carbonate and calcium carbonate as bone: a comparative study in patients with chronic kidney disease. XLI Congress ERA, Lisbon, 2004:106
24. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N, Ebihara I, Koide H: Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 65:1099-1104, 2004
25. Monier-Faugère M, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH: Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 60:1460-1468, 2001
26. Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai GA, Fischer MS, Lifrieri F, Manni M, Morosetti M, Moscaritolo E, Sardella D: PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 40:348-354, 2002
27. Salusky IB, Goodman WG, Kuizon BD, Lavigne J, Zahranik RJ, Gales B, Wang HJ, Elashoff RM, Jüppner H: Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 63:1801-1808, 2003
28. Malluche HH, Monier-Faugere MC, Wang G, Frazao JM, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG: Cinacalcet HCl reduces bone turn over and bone marrow fibrosa in hemodialysis patients with secondary hyperparathyroidism (HPT). XLI Congress ERA, Lisbon, 2004:218
29. Mansour J, Benyahia M, Harbouche L, Presne C, Moriniere P, Fournier A: Calcimetic AMG 073 at 50 and 100 mg per day. Kidney Int 64:2324-2325, 2003
30. Coburn J, Frazao J: Calcitriol in the management of renal osteodystrophy. Semin Dial 9:316-326, 1996
31. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 36:690-695, 1989
32. Delmez JA, Tindira CA, Windus DW, Norwood KY, Giles KS, Nighswander TL, Slatopolsky E: Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 3:96-102, 1992
33. Ben Hamida F, El Esper I, Compagnon M, Moriniere P, Fournier A: Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate-binder. Nephron 63:258-262, 1993
34. Braun J, Asmus H, Holzer R, Brunkhorst R, Krause R, Schulz W, Neumayer HH, Raggi P, Bommer J: Long-term comparison of a calcium-free phosphate-binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin Nephrol 62:104-115, 2004
35. Indridason OS, Quarles LD: Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int 57:282-292, 2000
36. Mccullough PA, Sandberg KR, Dumler F, Yanez JE: Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. J Nephrol 17:205-215, 2004
37. Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, Kabaya T, Nihei H: The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 42:303-309, 2003
38. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, Segre GV, Fenton S, Sherrard DJ: Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. Kidney Int 44:860-866, 1993
39. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC: Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15:1943-1951, 2004
40. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18:1731-1740, 2003
41. Bonifacio DL, Malineni K, Kadakia RA, Soman SS, Sandberg KR, Mccullough PA: Coronary calcification and cardiac events after percutaneous intervention in dialysis patients. J Cardiovasc Risk 8:133-137, 2001
42. Haydar AA, Hujairi NM, Covic AA, Pereira D, Rubens M, Goldsmith DJ: Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography. Nephrol Dial Transplant 19:2307-2312, 2004
43. Coladonato JA, Ritz E: Secondary hyperparathyroidism and its therapy as a cardiovascular risk factor among end-stage renal disease patients. Adv Ren Replace Ther 9:193-199, 2002
44. Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MV, Muenz LR, He DY, Nolan CR: Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65:1914-1926, 2004
45. Emmett M: A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int 66(suppl 90):S25-S32, 2004
46. Goldsmith DJ, Covic A, Sambrook PA, Ackrill P: Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 77:37-43, 1997
47. Locatelli F, Covic A, Chazot C, Leunissen K, Luno J, Yaqoob M: Optimal composition of the dialysate, with emphasis on its influence on blood pressure. Nephrol Dial Transplant 19:785-796, 2004
48. Fournier AE, Johnson WJ, Taves DR, Beabout JW, Arnaud CD, Goldsmith RS: Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. I. Association of bone disease with potentially etiologic factors. J Clin Invest 50:592-598, 1971
49. Fournier AE, Arnaud CD, Johnson WJ, Taylor WF, Goldsmith RS: Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. II. Factors affecting serum immunoreactive parathyroid hormone. J Clin Invest 50:599-605, 1971
50. Argiles A, Kerr PG, Canaud B, Flavier JL, Mion C: Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int 43:630-640, 1993
51. Martin D, Davis J, Miller G, Shatzen E: Regression of parathyroid hyperplasia by cinacalcet HCl in a rodent model of chronic kidney disease. ERA XLI Congress, Lisbon, 2004:318
52. Frazao J, Nicolini M, Torregrossa J, Kerr P, Jaeger PH, Sprague SM, Jadoul M, Mellotte G, Neyer U, Geiger H, Hagen EC, McCary L, Baker N, Turner S, Quarles LD: Cinacalcet HCl effectively reduces intact PHT and Ca x P irrespective of the severity of secondary hyperparathyroidism. ERA XLI Congress, Lisbon, 2004:219
53. Cunningham J, Chertow GM, Goodman WG, Danese M, Olson K, Klassen P, Drüeke T: The effect of cinacalcet HCl on parathyroidectomy fracture, hospitalisation and mortality in dialysis subjects with secondary hypeparathyroidism. ERA XLI Congress, Lisbon, 2004:219
54. Dusso AS: Vitamin D receptor: mechanisms for vitamin D resistance in renal failure. Kidney Int Suppl 85:S6-S9, 2003
55. Li Y, Amling M, Pirro A, Priemel M, Meuse J, Baron R, Delling G, Demay MB: Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism rickets and osteomalacia but not alopecia in vitamin D receptor ablated mice. Endocrinology 139:4391-4396, 1998
56. Panda DK, Miao D, Tremblay ML, Sirois J, Farookhi R, Hendy GN, Goltzman D: Targeted ablation of the 25-hydroxyvitamin D 1alpha-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci USA 98:7498-7503, 2001
57. Masuyama R, Nakaya Y, Katsumata S, Kajita Y, Uehara M, Tanaka S, Sakai A, Kato S, Nakamura T, Suzuki K: Dietary calcium and phosphorus ratio regulates bone mineralization and turnover in vitamin D receptor knockout mice by affecting intestinal calcium and phosphorus absorption. J Bone Miner Res 18:1217-1226, 2003
58. Cozzolino M, Lu Y, Finch J, Slatopolsky E, Dusso AS: p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 60:2109-2117, 2001
59. Silver J, Kilav R, Sela-Brown A, Naveh-Many T: Regulation of PTH secretion and synthesis and parathyroid cell proliferation. In: Drücke T, Salusky 1 (eds). The Spectrum of Renal Osteodystrophy. Oxford: Oxford University Press, 2001:25-52
60. Brown EM, Wilson RE, Eastman RC, Pallotta J, Marynick SP: Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab 54:172-179, 1982
61. Brown EM: Mechanisms underlying the regulation of parathyroid hormone secretion in vivo and in vitro. Curr Opin Nephrol Hypertens 2:541-551, 1993
62. Slatopolsky E, Bricker NS: The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 4:141-145, 1973
63. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E: Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64:1653-1661, 2003
64. Kos CH, Karaplis AC, Peng JB, Hediger MA, Goltzman D, Mohammad KS, Guise TA, Pollak MR: The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J Clin Invest 111:1021-1028, 2003
65. Tu Q, Pi M, Karsenty G, Simpson L, Liu S, Quarles LD: Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto the Gcm2 null background. J Clin Invest 111:1029-1037, 2003
66. St-Arnaud R, Arabian A, Travers R, Barletta F, Raval-Pandya M, Chapin K, Depovere J, Mathieu C, Christakos S, Demay MB, Glorieux FH: Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 141:2658-2666, 2000
67. Kinuta K, Tanaka H, Shinohara M: Vitamin D is a negative regulating factor in bone mineralisation. J Bone Miner Res 15:S180, 2000
68. Heaney RP, Barger-Lux MJ, Dowell MS, Chen TC, Holick MF: Calcium absorptive effects of vitamin D and its major metabolites. J Clin Endocrinol Metab 82:4111-4116, 1997
69. Goodman WG: Recent developments in the management of secondary hyperparathyroidism. Kidney Int 59:1187-1201, 2001
70. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ: Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327:1637-1642, 1992
71. Larsen ER, Mosekilde L, Foldspang A: Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: a pragmatic population-based 3-year intervention study. J Bone Miner Res 19:370-378, 2004
72. Bayard F, Bee P, Ton That H, Louvet JP: Plasma 25-hydroxycholecalciferol in chronic renal failure. Eur J Clin Invest 3:447-450, 1973
73. Liu S, Chu H: Studies of calcium phosphate metabolism with special reference to pathogenesis and effects of dihydrotachysterol and iron. Medicine 22:103-161, 1943
74. Llach F, Massry SG, Singer FR, Kurokawa K, Kaye JH, Coburn JW: Skeletal resistance to endogenous parathyroid hormone in pateints with early renal failure. A possible cause for secondary hyperparathyroidism. J Clin Endocrinol Metab 41:339-345, 1975
75. Lafage MH, Combe C, Fournier A, Aparicio M: Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int 42:1217-1225, 1992
76. Combe C, Aparicio M: Phosphorus and protein restriction and parathyroid function in chronic renal failure. Kidney Int 46:1381-1386, 1994
77. Lafage Proust M, Combe C, Barthe M, Aparicio M: Bone mass and dynamic parathyroid function according to bone histology in non dialyzed uremic patients after long term protein and phosphorus restriction. J Clin Endocrinol Metab 84:512-519, 1999
78. Schomig M, Ritz E: Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites. Nephrol Dial Transplant 15(suppl 5):18-24, 2000
79. Rix M, Eskildsen P, Olgaard K: Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant 19:870-876, 2004
80. Berl T, Berns AS, Hufer WE, Hammill K, Alfrey AC, Arnaud CD, Schrier RW: 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study. Ann Intern Med 88:774-780, 1978
81. Memmos DE, Eastwood JB, Talner LB, Gower PE, Curtis JR, Phillips ME, Carter GD, Alaghband-Zadeh J, Roberts AP, de Wardener HE: Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis. Br Med J (Clin Res Ed) 282(6280):1919-1924, 1981
82. Sebert JL, Fournier A, Gueris J, Meunier P: Limit by hyperphosphatemia of the usefulness of vitamin D metabolites in the treatment of renal osteodystrophy. Metab Bone Dis Relat Res 2:217-222, 1980
83. Fournier A, Bordier P, Bedrossian J, Marie A, Gueris J, Idatte J: Effect of phosphate binder on bone formation and resorption in patients on chronic hemodialysis with and without kidney. In: Norman AW (ed). Vitamin D and Problems Related to Uremic Bone Disease: Proceedings of the Second Workshop on Vitamin D, Wiesbaden, West Germany, October 1974. Berlin: Walter de Gruyter, 1975:577-584
84. Ward MK, Feest TG, Ellis HA, Parkinson IS, Kerr DN: Osteomalacic dialysis osteodystrophy: evidence for a water-borne aetiological agent, probably aluminium. Lancet 1(8069):841-845, 1978
85. Moriniere P, Roussel A, Tahiri Y, de Fremont JF, Maurel G, Jaudon MC, Gueris J, Fournier A: Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism. Proc Eur Dial Transplant Assoc 19:784-787, 1983
86. Moriniere P, Fournier A, Leflon A, Herve M, Sebert JL, Gregoire I, Bataille P, Gueris J: Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis. Nephron 39:309-315, 1985
87. 3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum. Nephron 53:93-101, 1989
88. Renaud H, Atik A, Herve M, Moriniere P, Hocine C, Belbrik S, Fournier A: Evaluation of vascular calcinosis risk factors in patients on chronic hemodialysis: lack of influence of calcium carbonate. Nephron 48:28-32, 1988
89. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O'Donnell CJ, Wilson PW: Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif Tissue Int 68:271-276, 2001
90. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27:394-401, 1996
91. Wilson PW, Kauppila LI, O'Donnell CJ, Kiel DP, Hannan M, Polak JM, Cupples LA: Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality. Circulation 103:1529-1534, 2001
92. Taal MW, Roe S, Masud T, Green D, Porter C, Cassidy MJ: Total hip bone mass predicts survival in chronic hemodialysis patients. Kidney Int 63:1116-1120, 2003
93. Sadek T, Mazouz H, Bahloul H, Oprisiu R, El Esper N, El Esper I, Boitte F, Brazier M, Moriniere P, Fournier A: Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant 18:582-588, 2003
94. 3 and low dialysate calcium. Kidney Int 43:S121-S124, 1993
95. 3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration. Nephron 71:254-283, 1995
96. Kuizon BD, Goodman WG, Juppner H, Boechat I, Nelson P, Gales B, Salusky IB: Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 53:205-211, 1998
97. Kestenbaum B, Seliger SL, Gillen DL, Wasse H, Young B, Sherrard DJ, Weiss NS, Stehman-Breen CO: Parathyroidectomy rates among United States dialysis patients: 1990-1999. Kidney Int 65:282-288, 2004
98. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446-456, 2003
99. Hayashi M, Tsuchiya Y, Itaya Y, Takenaka T, Kobayashi K, Yoshizawa M, Nakamura R, Monkawa T, Ichihara A: Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial. Nephrol Dial Transplant 19:2067-2073, 2004
100. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63:1483-1490, 2003
101. Goldfarb S: Syllabus: renal osteodystrophy, disorders of divalent ions and nephrolithiasis. In: Glassock RJ (ed). Neph SAP: Nephrology Self-Assessment Program. J Am Soc Nephrol 3:84-116, 2004
102. 3 selectively induces bone formation. Proc Natl Acad Sci USA 99:13487-13491, 2002
103. Fournier A, Pontoiero G, Walker R, Baker N, Turner S, Hörl WH: Cinacalcet HCl reduces parathyroid hormone and calcium phosphorus product regardless of concurrent changes in vitamin D administration. ERA XLI Congress, Lisbon, 2004:319
104. Schömig M, Ritz E: Management of disturbed calcium metabolism in uraemic patients: 2. Indications for parathyroidectomy. Nephrol Dial Transplant 15(suppl 5):25-29, 2000
105. Cunningham J: Calcium concentration in the dialysate and calcium supplements. Nephrol Dial Transplant 15(suppl 5):34-35, 2000
106. Drueke TB: Renal osteodystrophy: management of hyperphosphataemia. Nephrol Dial Transplant 15(suppl 5):32-33, 2000
107. Manns B, Stevens L, Miskulin D, Owen WF Jr, Winkelmayer WC, Tonelli M: A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 66:1239-1247, 2004
108. Alsheikh-Ali A, Aboujaily HM, Stanek LJ: Increases in HDL cholesterol are the strongest predictions of risk reduction in lipid intervention trials [abstract 3754]. Circulation 111 (suppl III):813, 2004